News

Events

'We're ripe': Cygnal draws the curtain on Flagship's latest bet on exoneural biology — and $65M in cash

10.08.2019 Endpoints

Cygnal Therapeutics emerges from ‘stealth mode’ with $65m in venture capital

10.08.2019 Boston Globe

Flagship unveils Cygnal, a nervy take on cancer, inflammation

10.08.2019 BioCentury

Flagship Pioneering Unveils Cygnal Therapeutics

10.08.2019 PRNewsWire

War of Nerves

09.17.2019 Science

Cygnal Therapeutics Appoints Pearl S. Huang as Chief Executive Officer

07.29.2019 PRNewsWire

Cell Symposia. Hallmark of Cancer, Nov. 17-19, 2019

11.07.2019 Exhibitor

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 26-30, 2019

10.28.2019 Exhibitor

FierceBiotech 4th Drug Development Forum, October 28-29, 2019

08.05.2019 Speaker